{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-24-000011","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.337171+00:00","generated_at":"2026-06-05T07:28:22.237713+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Biohaven reports Q4 net loss $144.8M, cash $385.5M; key pipeline data milestones in 2024","bullets":["Q4 2023 net loss $144.8M ($1.81/sh); non-GAAP adj net loss $128.9M ($1.61/sh).","Cash, equivalents & securities $385.5M as of Dec 31, 2023 (incl. $3.7M restricted).","Public offering closed Oct 2023: 11.76M shares at $22, net proceeds ~$242.4M.","BHV-1300 Phase 1 IgG lowering data expected late Q1/early Q2 2024.","Troriluzole Phase 3 OCD interim analysis topline results expected Q2 2024; taldefgrobep SMA data H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-24-000011","json":"https://secwatch.observer/filing/0001935979-24-000011.json","markdown":"https://secwatch.observer/filing/0001935979-24-000011.md","text":"https://secwatch.observer/filing/0001935979-24-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000011/0001935979-24-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000011/bhvn-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:28:22.237713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"244db127419ae92e3a447285b882fd2a38173c08","claim":"Biohaven Ltd. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597924000011/0001935979-24-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}